Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG | Grabenstrasse 11a, 8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.
“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.
Read moreTopadur Pharma AG and Oshen Holdings SA Partner to Develop a Treatment for Alopecia
Read moreTOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.
Read more
